Pharmaceutical Technology

MAY 10, 2023

XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023. The acquisition will give Gilead Sciences access to XinThera’s portfolio of two small molecule inhibitor programmes, one of which targets PARP1 to treat cancer and the other of which targets MK2 for inflammatory diseases.

Immune Response 130

Immune Response DNA Clinical Trials Clinical Trials 130

Pharma Business Blog

MAY 14, 2020

In light of that, we would like to invite you to our Pharma & Life Science webinar where we and other industry professionals will be discussing the impact of COVID-19 on the ITX and regulatory DNA on the pharma and life science industry. We look forward to welcoming you to our webinar. Register (free of charge) Register here >.

Life Science 52

Life Science DNA Clinical Trials Clinical Trials 52

pharmaphorum

MARCH 31, 2022

UK startup Sano Genetics has raised $11 million in first-round financing to develop its go-between service, which aims to overcome one of the big challenges in clinical research by connecting patients with trial sponsors. The post Sano raises $11m for patient and trial matchmaking platform appeared first on.

Trials 52

Trials Genetics DNA Clinical Trials 52

Drug Discovery World

AUGUST 3, 2023

In the first part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates the use of medical cannabis in drug discovery. Medical cannabis is often a first-thought when regarding plant-based medicines, but there remains public scepticism, arguably due to the regulations relating to the substance.

Medicine 52

Medicine Scientist Production Regulation 52

Scienmag

MARCH 15, 2021

The first vaccine has been administered in a comparative adjuvant trial of DNA prime/protein boost HIV vaccine regimens in Kericho, Kenya Credit: U.S. Military HIV Research Program SILVER SPRING, Md.

Vaccination 68

Vaccination Vaccine Trials DNA 68

The Pharma Data

DECEMBER 23, 2020

Joseph Kim , President and CEO of INOVIO, said, “We are very pleased to share peer-reviewed Phase 1 clinical data for INO-4800 published in The Lancet’s EClinicalMedicine , and are grateful for the support of all participants and investigator staff involved in the clinical trial.” . PLYMOUTH MEETING, Pa. ,

DNA 40

DNA Vaccination Vaccine Immune Response 40

JAMA Internal Medicine

AUGUST 27, 2023

In recent years, blood tests that look for circulating tumor DNA and biomarkers (termed liquid biopsies) have been developed. Most importantly, these blood tests are also being explored as multicancer early detection (MCED) tests for cancer screening in asymptomatic persons.

FDA Approval 76

FDA Approval DNA Clinical Trials Clinical Trials 76

Pharmaceutical Technology

APRIL 12, 2023

Foundation Medicine has announced it will supply a tissue-based test as a companion diagnostic for Bristol Myers Squibb’s (BMS) recently acquired ROS1/TRK inhibitor repotrectinib. FoundationOne CDx is a sequencing-based in vitro diagnostic device that can identify alterations in 324 genes from tumour samples.

Genome 130

Genome Genomics In-Vitro Gene 130

Medical Xpress

NOVEMBER 14, 2022

A 300-mg dose of bepirovirsen per week for 24 weeks results in sustained hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA loss in 9–10% of patients with chronic HBV infection, according to a study published online Nov. 8 in the New England Journal of Medicine.

DNA 48

DNA Trials Medicine 48

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. This marks the second time one of Janssen’s HIV vaccines failed after another showed disappointing results in the Phase IIb Imbokodo trial in August 2021.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

AUGUST 5, 2022

In June, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine Agency (EMA) recommended approving the treatment in this setting. This EC approval was based on findings from the parallel-group, double-blind, placebo-controlled, global Phase III OlympiA clinical trial of Lynparza versus placebo.

FDA Approval 147

FDA Approval DNA Clinical Trials Clinical Trials 147

Pharmaceutical Technology

JUNE 21, 2023

Talzenna is an oral inhibitor of poly ADP-ribose polymerase (PARP) that plays a role in repairing DNA damage. The regulatory approval was based on the findings obtained from the Phase III TALAPRO-2 trial.

FDA Approval 130

FDA Approval Gene DNA Medicine 130

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Pharmaceutical Technology

MARCH 10, 2023

Personalised medicines will also be developed at the centre. In an email to Pharmaceutical Technology , an NHSBT spokesperson said the centre will “support early phase clinical trials and preclinical work, providing a route to eventual commercial scale production”.

Gene Therapy 264

Gene Therapy Manufacturing Gene Clinical Trials 264

pharmaphorum

NOVEMBER 22, 2021

This forum will specifically focus on targeting mitochondrial dysfunction to develop therapies for chronic diseases caused by mitochondrial DNA mutation/nuclear DNA mutations, muscle dystrophy diseases/muscle loss, metabolic disorders, neurodegenerative disease, and conditions linked to oxidative damage.

Development 94

Development Drugs DNA Gene Therapy 94

Roots Analysis

JANUARY 28, 2024

Pharmaceutical Research: Big data analytics can be applied in various areas of pharmaceutical research, including drug discovery and development, precision medicine , clinical trial optimization, pharmacovigilance and drug safety, supply chain optimization, and real-time monitoring and surveillance.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

pharmaphorum

SEPTEMBER 13, 2021

A blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will start trials by the NHS in England involving around 140,000 subjects. The NHS-Galleri trial is being run by Cancer Research UK (CRUK) and King’s College London (KCL) in partnership with the NHS and Grail.

Trials 70

Trials DNA Scientist Medicine 70

Scienmag

JUNE 4, 2021

Targeted therapy shrank tumors, shows promise in improving survival Credit: Huy Mach/Washington University School of Medicine in St. Louis The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial.

Genetics 54

Genetics DNA Drugs Clinical Trials 54

Scienmag

MAY 25, 2021

These Oncotarget data reveal a new class of mibefradil-based DNA repair inhibitors which can be further advanced into pre-clinical testing and eventually clinical trials, as potential GBM radiosensitizers Credit: Correspondence to – Yulia V. Surovtseva – yulia.surovtseva@yale.edu and Ranjit S.

DNA 97

DNA Clinical Trials Clinical Trials Trials 97

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.

DNA 52

DNA Medicine Genome Genomics 52

Drug Discovery World

AUGUST 16, 2022

A precision medicine for early-stage breast cancer has been approved by the European Medicines Agency (EMA). . The OlympiA trial was the first to show that olaparib, which exploits a specific weakness in cancers with mutations in their BRCA1 or BRCA2 genes, is beneficial for patients when their cancer is at an early stage. .

DNA 52

DNA Gene Medicine Branding 52

pharmaphorum

DECEMBER 17, 2021

Read on for a look at some of the biggest stories from Frontiers Health, how digital is making healthcare more patient-friendly and key ways to optimise decentralised clinical trials. Digital health: making medicine more human. After years of slow growth in the sector digital healthcare tools are becoming commonplace in medicine.

Clinical Trials 98

Clinical Trials Clinical Trials Medicine DNA 98

Drug Discovery World

OCTOBER 20, 2023

The acquisition of Olink underscores the profound impact that proteomics is having as our customers continue to advance life science research and precision medicine,” said Marc Casper, Chairman, President and Chief Executive Officer of Thermo Fisher.

Drugs 52

Drugs Antibody DNA Gene Therapy 52

pharmaphorum

NOVEMBER 5, 2021

The phase 3 trial found that Paxlovid – which combines new protease inhibitor PF-07321332 with already-approved HIV drug ritonavir – reduced the risk of hospitalisation or death by 89% when given to newly-diagnosed adults who were at risk of developing severe COVID-19 in the EPIC-HR trial.

Contract Manufacturing 113

Contract Manufacturing DNA HR Manufacturing 113

Drug Discovery World

JULY 17, 2023

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine will start of a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases.

Protein 52

Protein DNA Clinical Trials Clinical Trials 52

Delveinsight

FEBRUARY 18, 2021

Bluebird suspends gene therapy trials after two sickle cell patients develop cancer. Bluebird bio has stopped two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

Drug Discovery World

AUGUST 5, 2022

Three key members of the team – Dr Raquel Sanches-Kuiper, Vice President of Technology, Dr Matthew Hayes, Chief Technology Officer and John Edgell, Head of Cloud Engineering – explain how the company is doing this and what it means for the advancement of DNA synthesis in the lab. The next goal is to optimise the technology. “At

DNA 52

DNA Engineer Gene Sequencing Gene 52

Drug Discovery World

SEPTEMBER 7, 2023

However, despite the fact that children’s response to adult cancer drugs is often poor, due to the challenges of developing medicines for this population, only six drugs are made specifically for childhood cancer. If the trial is successful, the ibrutinib/indoximod platform would readily transfer to other tumours and chemotherapy.

Drugs 59

Drugs Clinical Trials Clinical Trials Trials 59

Drug Discovery World

AUGUST 14, 2023

Over the past few decades, the incredible progress in personalised medicine has led to the development of life-saving cell and gene therapies (CGT). For instance, in a trial where patients are selected based on a specific human leukocyte antigen (HLA) type, the FDA requires the use of a fully certified, FDA approved Companion Diagnostic.

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

XTalks

FEBRUARY 14, 2024

OncoImmune was founded in 2000 based on the scientific discoveries of the company’s founders who moved their lead product from a basic concept into clinical trials for multiple indications. Previously, he served as CFO of Artios, a UK-based DNA damage response company where he led the company’s $153 million Series C fundraising.

Life Science 119

Life Science DNA Production Clinical Trials 119

pharmaphorum

OCTOBER 26, 2021

All three filings come within a few weeks of Merck and Ridgeback reporting the results of the MOVe-OUT trial, which revealed a significant 50% reduced risk of hospitalisation or death in these patients compared to placebo with the drug, cutting the rate to 7% from 14%. Pfizer’s drug is currently in late-stage clinical trials.

Drugs 103

Drugs DNA Trials Medicine 103

pharmaphorum

APRIL 7, 2021

billion-plus alliance with UK biotech Artios Pharma to develop precision medicines for cancer. The new deal with Artios allows Novartis to tap into Artios’ DDR technology platform, which focuses on compounds that can prevent cancer cells from repairing damage to their DNA via a process called synthetic lethality.

DNA 52

DNA Licensing Licensing Gene Therapy 52

Scienmag

MAY 28, 2021

The scientists analyzed short fragments of tumor DNA that are circulating in the blood. Credit: Tatjana Hirschmugl A new study exploits the characteristic epigenetic signatures of childhood tumors to detect, classify and monitor the disease.

DNA 96

DNA Genetics Scientist Clinical Trials 96

pharmaphorum

OCTOBER 7, 2020

Originally discovered in bacteria as a defense mechanism against pathogens, CRISP/Cas9 has made it possible to make exquisitely detailed and precise alterations to DNA sequences on demand, and as a tool for molecular biology has already transformed research into diseases and drug discovery. million) Nobel Prize award. “In

Gene Editing 96

Gene Editing Bacteria DNA Gene 96

pharmaphorum

NOVEMBER 9, 2022

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable levels of the virus compared to an earlier readout.

Drugs 96

Drugs Sales Trials DNA 96

Pharmaceutical Technology

FEBRUARY 24, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Amivantamab overview Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody developed using recombinant DNA technology.

Recombinant DNA Technology 100

Recombinant DNA Technology Production Antibody FDA Approval 100

The Pharma Data

JUNE 24, 2021

today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The TALAPRO-3 trial will enroll approximately 550 men with DDR-deficient mCSPC across 285 clinical trial sites in 28 countries. About TALAPRO-3 Trial.

DNA 52

DNA Clinical Trials Clinical Trials Trials 52